LAUSR

HCV-DC HBV-DC EtOH-DC NASH-DC Direct-acting antivirals (DAA) reduce post-transplant mortality DAAs have changed the natural history of hepatitis C virus (HCV) infection, but their impact on post-transplant outcomes is not clear. Belli et al. explored the European Liver Transplant Registry comprising over 60,000 patients, of whom 36,382 patients had HCV cirrhosis, to address this question. Their data showed a significant reduction in the percentage of patients transplanted for HCV from about 21% to about 11%. Additionally, the threeyear survival of HCV cirrhosis patients undergoing orthotopic liver transplantation improved from 65.1% in the IFN/RBV era to 76.9% in the DAA era. The data provide clear and exciting evidence of the huge impact of DAAs on the outcome of liver transplantation for HCV cirrhosis. Belli et al., 2018 Direct-acting antivirals (DAAs) reduce post-transplant mortality